A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Low Grade Ovarian Serous Adenocarcinoma · Ovarian Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
- +10
Main results were due Nov 2024, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 2
- Patients
- 225 (planned)
- Started
- Dec 21, 2020
- Main results expected
- Nov 15, 2024
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinib
Measured over: From start of treatment to confirmation of response; 24 weeks
Part B: To determine the efficacy of the optimal regimen identified from Part A
Measured over: From start of treatment to confirmation of response; 24 weeks
Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part A
Measured over: From start of treatment to confirmation of response; 24 weeks
Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib
Measured over: From start of treatment to confirmation of response; 24 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
- results_overdue: base 10, now 10, since 2024-11-15, no fading
Raw record changes
- none yet
Trial ID NCT04625270 · record last updated 2025-01-29 · checked 2026-11-09 06:30 UTC